Sa3

SA3 is an early-stage biotechnology company focused on developing novel therapeutic interventions targeting the STAG3 protein, a key component of the cohesin complex. The company leverages its proprietary platform to identify and optimize small molecule inhibitors and peptide-based therapies designed to disrupt oncogenic signaling in various solid tumors. By targeting the specific vulnerabilities associated with STAG3 overexpression or mutation, SA3 aims to provide precision medicine solutions for patients with limited treatment options. The company's research is grounded in deep expertise in chromosome biology and structural proteomics.